𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Amisulpride Does Not Prevent Relapse in Primary Alcohol Dependence: Results of a Pilot Randomized, Placebo-Controlled Trial

✍ Scribed by Donata Marra; Dominique Warot; Ivan Berlin; Eric Hispard; Christine Notides; Samir Tilikete; Christine Payan; Jean-Pierre Lépine; Sylvain Dally; Henri-Jean Aubin

Book ID
109122057
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
130 KB
Volume
26
Category
Article
ISSN
0145-6008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Spironolactone Does Not Prevent Acute Mo
Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group)
✍ Buddha Basnyat; Peter S. Holck; Matiram Pun; Stephen Halverson; Piotr Szawarski; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 564 KB

## Objectives: Over the last 20 years a number of small trials have reported that spironolactone effectively prevents acute mountain sickness (ams), but to date there have been no large randomized trials investigating the efficacy of spironolactone in prevention of ams. hence, a prospective, double

Interferon-α does not improve outcome at
Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial
✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal